Search
leukocyte surface antigen CD47; integrin-associated protein; IAP; antigenic surface determinant protein OA3; protein MER6; CD47 (CD47, MER6)
Function:
- thrombospondin receptor
- role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, & in modulation of integrins
- role in memory formation & synaptic plasticity in the hippocampus (putative)
- receptor for SIRPA, binding to which prevents maturation of immature dendritic cells & inhibits cytokine production by mature dendritic cells
- interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation & costimulates T-cell activation
- may play a role in membrane transport &/or integrin dependent signal transduction
- may prevent premature elimination of red blood cells
- may be involved in membrane permeability changes induced following virus infection
- interacts with THBS1 & fibrinogen (putative)
- interacts with SIRPA, SIRPG, UBQLN1 & UBQLN2
Structure:
- monomer
- similar to Rh antigen
- contains 1 Ig-like V-type domain (immunoglobulin-like)
Compartment: cell membrane; multi-pass membrane protein
Alternative splicing:
- named isoforms=4
- at least one isoform may be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay
Expression:
- widely distributed
- hematopoietic cells
- epithelial cells
- endothelial cells
- fibroblasts
- mesenchymal cells
- brain
Pathology:
- expressed in:
- misc tumor cell lines
- ovarian tumors
- CD47 expression on the surface of cancer cells may help them evade to immune system [4]
Pharmacology:
- CD47 antibody suggested as possible treatment of all cancers
General
cluster-of-differentiation antigen; cluster designation antigen; CD antigen
glycoprotein
immunoglobulin superfamily protein
transmembrane 5 protein
Properties
SIZE: entity length = 323 aa
MW = 35 kD
COMPARTMENT: plasma membrane
MOTIF: exoplasmic domain {19-141}
MOTIF: signal sequence {1-18}
immunoglobulin superfamily domain {19-127}
MOTIF: N-glycosylation site {N23}
cysteine residue {C33}
MODIFICATION: cysteine residue {C263}
N-glycosylation site {N34}
cysteine residue {C41}
MODIFICATION: cysteine residue {C114}
N-glycosylation site {N50}
N-glycosylation site {N73}
N-glycosylation site {N111}
cysteine residue {C114}
MODIFICATION: cysteine residue {C41}
transmembrane domain {142-162}
cytoplasmic loop {163-176}
transmembrane domain {177-197}
exoplasmic loop {198-207}
MOTIF: N-glycosylation site {N206}
transmembrane domain {208-228}
cytoplasmic loop {229-235}
transmembrane domain {236-256}
exoplasmic loop {257-268}
MOTIF: cysteine residue {C263}
MODIFICATION: cysteine residue {C33}
transmembrane domain {269-289}
cytoplasmic domain {290-323}
Database Correlations
OMIM 601028
UniProt Q08722
PFAM correlations
Entrez Gene 961
Kegg hsa:961
References
- http://www.pathologyoutlines.com/cdmarkers.html
15 October 2002
- UniProt :accession Q08722
- Entrez Gene :accession 961
- http://sfbay.ca/2013/07/13/antibody-could-eliminate-cancer-researchers-say/#ixzz2Z2oRYVad